Q&A Genmab 2020-11-27

	27/11 16:28 af Jan Van de Winkel	We are currently analyzing the liver tox seen in some patients. At present it is too early to speculate on the mechanism of action but we are encouraged by our ability to manage the tox profile in cancer patients. 2021 will be the year where we will hope to see data from the expansion cohort with this antibody and to get a better feeling of the mechanism underlying the toxicity in some of the patients.
	27/11 16:28 af Sukkeralf	Jan could you disclose any hints about the split between the development/registration percentage and the sales percentage in the milestone package for the Janssen DuoBody deal - just to get a feel of how backloaded these are ?
	27/11 16:30 af Jan Van de Winkel	We are entitled to milestones on the various programs of between 170-190 m USD and royalties usually in the single digits range. Our partners do not want us to provide further color.
	27/11 16:31 af Sujit k	On JNJ-63898081 (for solid tumors): Any comments on how the program is doing? (using your DuoBody platform)-- when to expect a potential update on this program?
	27/11 16:32 af Jan Van de Winkel	This is a JnJ program which is progressing well. Updates will come from JnJ.
	27/11 16:32 af Selva K	As part of the collaboration with JNJ, do you have any plans to expand the JNJ-63898081 program to broad solid tumors?
	27/11 16:33 af Jan Van de Winkel	The planning for this program is entirely up to JnJ.
	27/11 16:33 af Selva K	while Genmab has received milestone from JNJ for JNJ-63898081 in July 2019, when do you expect next milestone under the JNJ deal? May be can pls talk the Program?
	27/11 16:34 af Jan Van de Winkel	We cannot comment on timing.
	27/11 16:35 af Jan Van de Winkel	At present there are no plans to work on the denomination of the Danish shares.
	27/11 16:37 af Jan Van de Winkel	We intend to create further value for our exciting differentiated antibody products which will require maximization of a number of programs and thus substantial investments...
	27/11 16:37 af Jan Van de Winkel	Next February we will provide guidance for 2021. Stay tuned.
	27/11 16:39 af Jan Van de Winkel	Our ambition is to become a fully integrated biotech innovation powerhouse and achieve our 2025 vision of bringing truly innovative antibody therapeutics to patients.
	27/11 16:39 af Sujit k	Any update on Genmab/ Janssen PSMA molecule, any plans for interim data next year?
	27/11 16:40 af Jan Van de Winkel	Updates will come from JnJ.
	27/11 16:40 af aarfaei	Regarding, enapotamab vedotin, was the primary issue safety or efficacy?
	27/11 16:41 af Jan Van de Winkel	It is a combination of both.
	27/11 16:41 af GeorgeBest	If Sanofi succeeds in developing a SC formulation for Sarclisa, do you see this as a big risk for Darzalex to lose substantial marketshare?
	27/11 16:42 af Jan Van de Winkel	At present we see daratumumab getting more and more traction as a lead therapeutic for MM. The current subcu formulation is increasingly adding to this leadership position.
	27/11 16:43 af Solsen	Mr Winkel One more on GEN1046 as for understanding the duobody. Can the binding to the 4-1BB arm take place if the PD-L1 arm are “free”
	27/11 16:44 af Jan Van de Winkel	This antibody has been designed to only activate T-cells via the 41BB molecule when the PD-L1 targeting arm of the bispecific is bound to a cell.
	27/11 16:44 af Helge Larsen/PI-redaktør	And now to the last question.
	27/11 16:44 af NJäger	How would you describe your personal style of leadership as a CEO?
	27/11 16:46 af Jan Van de Winkel	I am very much a team player and setting ambitious goals with a fabulous team working in very close collaboration and at a high pace.

	27/11 16:46 af Helge Larsen/PI-redaktør	Thank you for joining us and thank you for the many fullfilling answers to our questions. We look forward to seeing you back here on ProInvestor.com after Q4.
	27/11 16:47 af Jan Van de Winkel	Thank you for another energizing session. Looking forward to our next chat...
	27/11 16:47 af Jan Van de Winkel	Stay safe and keep optimistic.
	27/11 16:48 af Helge Larsen/PI-redaktør	This session has ended.